Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Covagen AG

Next-generation multivalent and bispecific biologics

This article was originally published in Start Up

Executive Summary

Next-generation bispecific “antibody-like” protein drug technologies boast the as-yet-unproven ability to deliver synergistically dual-acting therapeutics with the properties of two monoclonal antibodies in a single molecule, but the key to these emerging technologies’ success depends on their protein-binding moieties.  Covagen AG contends that its Fynomers technology solves many of the problems that hold back current bispecific antibody therapies.

You may also be interested in...



With A New CSO, Bristol-Myers Squibb Doubles Down On Immuno-Oncology

BMS’ strategy for the complex, highly competitive immuno-oncology field. A Q&A with the company’s new R&D chief, lung cancer specialist Thomas Lynch, MD.

Patheon Tightens The Supply Chain To Transform Pharma Outsource Manufacturing

Fueled by a series of strategic acquisitions, Patheon hopes to become the biopharma industry’s first single-source, end-to-end manufacturing service provider.

Polaris Stays Disciplined For Breakthroughs: An Interview With Alan Crane

The demands of building new biotechs can take their toll, yet Alan Crane wears his 52 years and over two decades of high-risk biotech start-up investing lightly. He's built an exceptional number of companies during his tenure at Polaris, many of which have proved to be among the industry’s more successful emerging ventures.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

OM013626

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel